Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP vs TI-CE as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
NCT02375204Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2015
- Primary completion
- Jun 2031
- Modality
- DNA Intercalators/Alkylators
- Countries
- 12
01
Overview
A Phase 3 trial of carboplatin, etoposide phosphate in germ cell tumor (GCT), sponsored by Cancer and Leukemia Group B. Started Aug 2015; status: active, not recruiting.
02
Drugs
carboplatinetoposide phosphate
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02375204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375204.